Join to View Full Profile
10 Center DrBethesda, MD 20814
Phone+1 216-444-2200
Dr. Pleyer is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 2016 - 2019
Cleveland Clinic FoundationResidency, Internal Medicine, 2013 - 2016
OtherClass of 2012
Certifications & Licensure
DC State Medical License 2018 - 2027
CA State Medical License 2018 - 2026
OH State Medical License 2013 - 2021
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- 3 citationsInterruption of BTK inhibitor improves response to SARS-CoV-2 booster vaccination in patients with CLL.Emily Tomasulo, Shira Paul, Rui Mu, Xin Tian, Jonathan Chen
Leukemia & Lymphoma. 2023-12-01 - 17 citationsBTK inhibitors impair humoral and cellular responses to recombinant zoster vaccine in CLL.Christopher Pleyer, Kerry J Laing, Mir A Ali, Christopher L McClurkan, Susan Soto
Blood Advances. 2022-03-22 - 17 citationsCOVID-19 vaccines for patients with haematological conditions.Clare Sun, Christopher Pleyer, Adrian Wiestner
The Lancet. Haematology. 2021-03-31
Lectures
- Response to the Shingrix Varicella Zoster Virus (VZV) Vaccine in Patients with Chronic Lymphocytic Leukemia (CLL) That Are Treatment Naive or Treated with a Bruton's T...61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- Partial Reconstitution of Humoral and Cellular Immunity in Patients with Chronic Lymphocytic Leukemia Treated with Acalabrutinib2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Partial Reconstitution of Humoral and Cellular Immunity in Patients with Chronic Lymphocytic Leukemia Treated with Acalabrutinib2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
